Observational analyses from ADVANCE and ADVANCE-ON.
Although the Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation (ADVANCE) study was designed as a multicentre randomised factorial placebo-controlled clinical trial, from the outset it was envisaged that the study would be extended to include observational analyses. Thus, a post-randomization follow-up of patients surviving past the end of the clinical trial was planned, to explore legacy effects, and epidemiological studies using the trial data, but treating the study population as an epidemiological cohort, were planned. This article will describe operations and findings from both types of observational analyses. Additionally, we briefly review meta-analyses which ADVANCE has contributed to, and discuss future plans. This article is protected by copyright. All rights reserved.